|
|
||||||||
Brief Communication |
Address correspondence to Soo Hwan Pai, M.D., Department of Laboratory Medicine, Inha University Hospital, 7-206, 3-ga, Shinheung-dong, Jung-gu, Inchon, 400-711, South Korea; tel 82 32 890 2503; fax 82 32 890 2529; e-mail shpaimd{at}inha.ac.kr.
Abstract
To investigate the relationships of tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), anthropometric variables, and lipid parameters, we measured serum TRAIL concentrations, body mass index (BMI), total body fat (TBF), and serum lipid profiles in 207 healthy adults. There were no significant differences in serum TRAIL concentrations between men and women, nor between elderly persons and middle-aged subjects. However, men with TBF 16.4 kg (75th per centile) exhibited significantly higher serum TRAIL concentrations than those with TBF 11.2 kg (25th per centile) (69.7 ± 15.1 pg/ml vs 50.2 ± 14.3 pg/ml, p <0.05). Serum TRAIL concentration averaged 76.2 ± 16.1 pg/ml in women with low-density lipoprotein cholesterol (LDL-C) 165 mg/dl (75th per centile), which was significantly above the values (53.1 ± 12.9 pg/ml, p <0.05) in those with LDL-C 117 mg/dl (25th per centile), although no differences were observed on the basis of TBF (75th percentile vs 25th percentile). Serum TRAIL concentrations correlated significantly with TBF (r = 0.31, p <0.05) and lean body mass (r = 0.26, p <0.05) in men and LDL-C (r = 0.32, p <0.05) and total cholesterol (r = 0.21, p <0.05) in women. In conclusion, serum TRAIL concentrations are associated with serum lipid levels and body adiposity in healthy adults, but are unrelated to a subjects age or gender.
(received 30 June 2004; accepted 2 August 2004)
Keywords: tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), total body fat, serum lipid levels, low-density lipoprotein cholesterol
Introduction
Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is a TNF superfamily member [1,2]. TRAIL is transmembrane protein expressed on cell surfaces and has a broad expression pattern in a variety of organs [3]. TRAIL is capable of inducing apoptosis in lymphoid and non-lymphoid tumor cell lines, thus providing an exciting prospect for development of therapeutic strategies in cancer [4]. In normal physiology, TRAIL is thought to act in tumor suppression and immune cell homeostasis, and also to play a role in viral-induced diseases [5].
Obesity is a condition with abnormally increased body fat, resulting from increased energy intake relative to energy expenditure. Numerous epidemiological studies have shown that obesity is directly associated with the risk of cancer at several organ sites, including colon, breast, and endometrium [6,7]. These associations with cancer risk are explained by alterations in steroid hormone and insulin-like growth factor levels, which can lead to distortion of the normal balance between cell proliferation, differentiation, and apoptosis [8]. Increased serum lipid levels have been reported to be significantly associated with apoptosis in animal studies [9,10]. Some investigators demonstrated that TNF-
plays an important role in multiple aspects of adipose tissue biology and mediates the abnormalities that occur at this site in obesity [11]. Despite intense research, data for the changes in serum TRAIL concentrations in healthy subjects, especially in relation to body adiposity and serum lipid profiles, are limited. In the present study, we tested whether serum TRAIL concentration correlates significantly with total body fat (TBF), body mass index (BMI), and serum lipid concentrations. We also investigated whether serum TRAIL concentrations change with subjects age and gender in apparently healthy individuals.
Materials and Methods
A total of 207 adults (91 men, 116 women) with a median age of 61 yr (range 5072 yr) were investigated by measurements of serum TRAIL concentrations and serum lipid profiles, including total cholesterol, triglycerides, low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C). To minimize the influence of age and hormonal effects on serum lipid levels and TBF, only postmenopausal women and age-matched men were enrolled in this study. The women were judged to have reached menopause if they had not menstruated for 12 mo prior to the inv estigation. Five subjects with postmenopausal hormone replacement therapy (n = 3) or acute and chronic diseases (n = 2) were excluded from study.
Four anthropometric parameters were measured in all subjects. The anthropometric indices included body weight, height, waist-to-hip ratio (WHR), and BMI (kg/m2). Body fat and lean body mass were assessed using a 8-polar tactile-electrode impedance-meter (body composition analyzer, InBody 3.0, Biospace Inc, Seoul, Korea), as described previously [12]. The subjects were all Korean, with no significant differences in race or socioeconomic status among the groups. The study was approved by the Ethics Committee of Inha University Hospital; informed consent was obtained from all subjects.
After the subjects had fasted for >12 hr, venous blood was drawn into an evacuated serum separator tube. Serum TRAIL concentrations were measured by an enzyme immunoassay (Quantikine human TRAIL/TNFSF10 kit, R&D Systems Inc, Minneapolis, MN, USA). Serum lipid profiles were assayed with an automatic chemical analyzer (Hitachi 747, Hitachi Corp, Tokyo, Japan) within 4 hr after collection. Serum triglyceride, total cholesterol, HDL-C, and LDL-C concentrations were analyzed by enzymatic colorimetric methods using triglyceride GPO-PAP reagents (Roche Diagnostics GmbH, Mannheim, Germany), SICDIA L T-CHO reagents (Eiken Chemical Industries, Tokyo, Japan), Cholestest-HDL reagents (Daiichi Chemicals, Tokyo, Japan), and Cholestest-LDL reagents (Daiichi Chemicals), respectively.
To investigate differences in serum TRAIL concentrations in relation to subjects age and gender, the subjects were assigned to 4 groups: men and women 5055 yr of age (median age, 53 yr, n = 52), 5660 yr (median age, 57 yr, n = 58), 6165 yr (median age, 62 yr, n = 50), and >65 yr (median age, 69 yr, n = 47), respectively. The subject population was also divided into 2 groups: women in one group; men in the other group. This was done according to the values of TBF and LDL-C: men with TBF 16.4 kg (75th per centile; n = 23) and TBF 11.2 kg (25th per centile; n = 23); women with LDL-C 165 mg/dl (75th per centile; n = 29) and LDL-C 117 mg/dl (25th per centile; n = 29).
Data analysis was performed with the SAS software package (SAS Institute, Cary, NC, USA). A non-parametric test (Wilcoxon rank sum test) was used to test the statistical significance of inter-group differences. Correlation coefficients were calculated by the Spearman method. All p values <0.05 were considered statistically significant.
Results and Discussion
In this study, we investigated the relationships of anthropometric variables, body composition, and serum lipid parameters vs serum TRAIL concentrations in healthy adults. We found that serum TRAIL concentrations are closely associated with body composition and serum lipid levels, especially TBF in men and LDL-C in women. Mean values of serum TRAIL concentrations in the subjects are summarized in Table 1
. Women showed a propensity towards slightly higher values of serum TRAIL concentrations compared to men, but this trend was not statistically significant. No differences were observed in serum TRAIL concentrations between persons >65 yr and subjects 5055 yr of age. These results suggest that subjects age or gender do not significantly influence serum TRAIL concentrations, at least in individuals >50 yr of age.
|
|
|
|
In conclusion, serum TRAIL concentrations showed significant correlations with serum LDL-C and TBF in men and women 50 yr of age, suggesting that the expression of soluble TRAIL may be related to lipid metabolism in elderly persons. Serum TRAIL level does not seem to differ according to age or gender in healthy adults. Further experiments regarding TRAIL receptors and apoptosis may explain why serum TRAIL concentrations correlate with TBF and LDL-C in elderly persons.
Acknowledgement
This study was supported by a research grant from the Medical Association of Inchon Metropolitan City in the Republic of Korea.
References
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |